STZ Stock Analysis: Constellation Brands | NYSE
Beverages - Brewers | NYSE, USA | Market Cap: 22.180m USD | 12M Return: 2.2% | US21036P1084 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 271M
EPS Trend: -16.4%
Qual. Beats: 0
Rev. Trend: -78.6%
Qual. Beats: 4
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Constellation Brands, Inc. (STZ) is a multinational alcoholic beverage producer headquartered in Rochester, New York, founded in 1945. The company produces, imports, markets, and sells beer, wine, and spirits across the United States, Canada, Mexico, New Zealand, and Italy. Its beer portfolio features well-known Mexican brands such as Corona Extra, Modelo Especial, and Pacifico, while its wine offerings include Kim Crawford, Ruffino, Robert Mondavi Winery, and The Prisoner Wine Company. Its spirits segment includes Casa Noble, High West, and Nelsons Green Brier. Products are distributed through wholesale distributors, retailers, and state alcohol beverage control agencies.
Operating within the Consumer Staples sector (GICS Sub Industry: Distillers & Vintners), Constellation Brands benefits from the relatively stable demand characteristic of alcoholic beverages. In the United States, the industry typically relies on a three-tier distribution framework-separating producers, wholesalers, and retailers-which shapes how companies like STZ bring products to market.
- Modelo Especial gains market share boosting beer segment revenue
- Mexican import tariffs threaten beer cost margins and pricing power
- Wine and Spirits divestiture with Blackstone unlocks shareholder value
| Net Income: 1.92b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA -0.29 > 1.0 |
| NWC/Revenue: -0.05% < 20% (prev 2.28%; Δ -2.33% < -1%) |
| CFO/TA 0.12 > 3% & CFO 2.66b > Net Income 1.92b |
| Net Debt (10.9b) to EBITDA (3.25b): 3.34 < 3 |
| Current Ratio: 1.00 > 1.5 & < 3 |
| Outstanding Shares: last quarter (170.6m) vs 12m ago -3.03% < -2% |
| Gross Margin: 52.65% > 18% (prev 51.43%; Δ 1.22% > 0.5%) |
| Asset Turnover: 42.36% > 50% (prev 44.93%; Δ -2.57% > 0%) |
| Interest Coverage Ratio: 8.38 > 6 (EBIT TTM 2.84b / Interest Expense TTM 338.7m) |
| A: -0.00 (Total Current Assets 2.96b - Total Current Liabilities 2.96b) / Total Assets 22.1b |
| B: 0.65 (Retained Earnings 14.4b / Total Assets 22.1b) |
| C: 0.13 (EBIT TTM 2.84b / Avg Total Assets 21.7b) |
| D: 0.65 (Book Value of Equity 8.59b / Total Liabilities 13.2b) |
| Altman-Z'' = 3.69 = AA |
| DSRI: 0.75 (Receivables 678.1m/946.0m, Revenue 9.21b/9.62b) |
| GMI: 0.98 (GM 51.43% / 52.65%) |
| AQI: 1.02 (AQ_t 0.47 / AQ_t-1 0.46) |
| SGI: 0.96 (Revenue 9.21b / 9.62b) |
| TATA: -0.03 (NI 1.92b - CFO 2.66b) / TA 22.1b) |
| Beneish M = -3.28 (Cap -4..+1) = AA |
As of October 24, 2026, the stock is trading at USD 138.68 with a total of 1,957,990 shares traded. Over the past week, the price has changed by +5.58%, over one month by +18.97%, over three months by +8.12% and over the past year by +2.16%.
Current recommended Stop Loss: 134.30 (which is 3.2% or 1.3 ATR below the current price).
Constellation Brands has received a consensus analysts rating of 3.96. Therefore, it is recommended to buy STZ.
- StrongBuy: 11
- Buy: 3
- Hold: 8
- Sell: 2
- StrongSell: 0
| Analysts Target Price | 150.9 | 8.8% |
P/E Trailing = 11.7341
P/E Forward = 10.02
P/S = 2.4086
P/B = 2.4325
P/EG = 1.495
Revenue TTM = 9.21b USD
EBIT TTM = 2.84b USD
EBITDA TTM = 3.25b USD
Long Term Debt = 9.69b USD (from longTermDebt, last fiscal year)
Short Term Debt = 1.22b USD (from shortTermDebt, last quarter)
Debt = 10.9b USD (from shortLongTermDebtTotal, last quarter) + Leases 634.1m
Net Debt = 10.9b USD (calculated: Debt 10.9b - CCE 98.5m)
Enterprise Value = 33.0b USD (22.2b + Debt 10.9b - CCE 98.5m)
Interest Coverage Ratio = 8.38 (Ebit TTM 2.84b / Interest Expense TTM 338.7m)
EV/FCF = 17.96x (Enterprise Value 33.0b / FCF TTM 1.84b)
FCF Yield = 5.57% (FCF TTM 1.84b / Enterprise Value 33.0b)
FCF Margin = 19.97% (FCF TTM 1.84b / Revenue TTM 9.21b)
Net Margin = 20.90% (Net Income TTM 1.92b / Revenue TTM 9.21b)
Gross Margin = 52.65% ((Revenue TTM 9.21b - Cost of Revenue TTM 4.36b) / Revenue TTM)
Gross Margin QoQ = 52.91% (prev 54.29%)
Tobins Q-Ratio = 1.50 (Enterprise Value 33.0b / Total Assets 22.1b)
Interest Expense / Debt = 3.09% (Interest Expense 338.7m / Debt 10.9b)
Taxrate = 19.08% (471.8m / 2.47b)
NOPAT = 2.30b (EBIT 2.84b * (1 - 19.08%))
Current Ratio = 1.00 (Total Current Assets 2.96b / Total Current Liabilities 2.96b)
Debt / Equity = 1.28 (Debt 10.9b / totalStockholderEquity, last quarter 8.59b)
Debt / EBITDA = 3.34 (Net Debt 10.9b / EBITDA 3.25b)
Debt / FCF = 5.90 (Net Debt 10.9b / FCF TTM 1.84b)
Total Stockholder Equity = 8.16b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.85% (Net Income 1.92b / Total Assets 22.1b)
RoE = 23.58% (Net Income TTM 1.92b / Total Stockholder Equity 8.16b)
RoCE = 15.91% (EBIT 2.84b / Capital Employed (Equity 8.16b + L.T.Debt 9.69b))
RoIC = 11.36% (NOPAT 2.30b / Invested Capital 20.2b)
WACC = 4.54% (E(22.2b)/V(33.1b) * Re(5.54%) + D(10.9b)/V(33.1b) * Rd(3.09%) * (1-Tc(0.19)))
Discount Rate = 5.54% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -99.47 | Cagr: -3.18%
[DCF] Terminal Value 75.38% ; FCFF base≈1.84b ; Y1≈1.84b ; Y5≈1.94b
[DCF] Fair Price = 114.1 (EV 30.2b - Net Debt 10.9b = Equity 19.3b / Shares 169.2m; r=8.35% [WACC [floored]]; 5y FCF grow -0.48% → 2.50% )
EPS Correlation: -16.39 | EPS CAGR: -1.00% | SUE: 0.67 | # QB: 0
Revenue Correlation: -78.61 | Revenue CAGR: -3.93% | SUE: 2.01 | # QB: 4
EPS current Quarter (2026-11-30): EPS=2.72 | Chg30d=-4.29% | Revisions=-68% | Analysts=19
EPS current Year (2027-02-28): EPS=11.82 | Chg30d=+0.24% | Revisions=-4% | GrowthEPS=-0.0% | GrowthRev=-0.2%
EPS next Year (2028-02-29): EPS=12.10 | Chg30d=-2.11% | Revisions=-71% | GrowthEPS=+2.4% | GrowthRev=+1.5%
[Analyst] Revisions Ratio: -52% (up=14, down=47)